

ANDA No.	Drug	Applicant
88-067	Orphenadrine Citrate S. R. Tablets, 100 mg	Do.
88-117	Triprolidine Hydrochloride Tablets, 2.5 mg Pseudoephedrine Hydrochloride Tablets, 60 mg.	West-Ward Pharmaceutical Corp.
88-199	Folic Acid Tablets, 1 mg	Unit Dose Laboratories.
88-256	Meclizine Hydrochloride Tablets, 12.5 mg	Do.
88-257	Meclizine Hydrochloride Tablets, 25 mg	Do.
88-288	Bethanechol Chloride Tablets, 10 mg	Ascot Hospital Pharmaceuticals, Inc.
88-289	Bethanechol Chloride Tablets, 25 mg	Do.
88-307	Thioridazine Hydrochloride Oral Concentrate, 30 mg/milliliters (mL).	Geneva Pharmaceuticals, Inc., 2555 West Midway Blvd., Broomfield, CO 80038-0446.
88-308	Thioridazine Hydrochloride Oral Concentrate, 100 mg/mL .	Do.
88-318	Triprolidine Hydrochloride Tablets, 2.5 mg Pseudoephedrine Hydrochloride Tablets, 60 mg.	Circa Pharmaceuticals.
88-332	Thioridazine Hydrochloride Tablets, 10 mg	Mylan Pharmaceuticals, Inc.
88-333	Thioridazine Hydrochloride Tablets, 25 mg	Do.
88-334	Thioridazine Hydrochloride Tablets, 50 mg	Do.
88-335	Thioridazine Hydrochloride Tablets, 100 mg	Do.
88-582	Quinidine Gluconate Sustained Release Tablets, 324 mg .	Ascot Hospital Pharmaceuticals, Inc.
88-646	Methocarbamol Tablets, 500 mg	Roxane Laboratories, Inc.
89-079	Nitroglycerin Controlled Release Capsules, 9 mg	Ascot Hospital Pharmaceuticals, Inc.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the ANDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective on May 26, 1995.

Dated: April 10, 1995.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 95-10272 Filed 4-25-95; 8:45 am]

BILLING CODE 4160-01-F

Health Resources and Services Administration

Advisory Commission on Childhood Vaccines; Request for Nominations for Voting Members

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Health Resources and Services Administration (HRSA) is requesting nominations to fill three vacancies on the Advisory Commission on Childhood Vaccines (ACCV). The ACCV was established by title XXI of the Public Health Service Act (the Act), as enacted by Public Law (Pub. L.) 99-660 and as subsequently amended, and advises the Secretary of Health and Human Services (the Secretary) on issues related to implementation of the National Vaccine Injury Compensation Program (VICP).

FOR FURTHER INFORMATION CONTACT: Mr. Jerry Anderson, Principal Staff Liaison, Policy and Commission Branch,

Division of Vaccine Injury Compensation, at (301) 443-1533.

DATES: Nominations are to be submitted by May 26, 1995.

ADDRESSES: All nominations are to be submitted to the Director, Division of Vaccine Injury Compensation, Bureau of Health Professions, HRSA, Parklawn Building, Room 8A-35, 5600 Fishers Lane, Rockville, Maryland 20857.

SUPPLEMENTARY INFORMATION: Under the authorities that established the ACCV, viz., the Federal Advisory Committee Act of October 6, 1972 (P.L. 92-463) and section 2119 of the Act, 42 U.S.C. 300aa-19, as added by P.L. 99-660 and amended, HRSA is requesting nominations for three voting members of the ACCV.

The ACCV advises the Secretary on the implementation of the VICP; on its own initiative or as the result of the filing of a petition, recommends changes in the Vaccine Injury Table; advises the Secretary in implementing the Secretary's responsibilities under section 2127 regarding the need for childhood vaccination products that result in fewer or no significant adverse reactions; surveys Federal, State, and local programs and activities relating to the gathering of information on injuries associated with the administration of childhood vaccines, including the adverse reaction reporting requirements of section 2125(b); advises the Secretary on means to obtain, compile, publish, and use credible data related to the frequency and severity of adverse reactions associated with childhood vaccines; and recommends to the Director, National Vaccine Program, Office of the Assistant Secretary for Health, research related to vaccine injuries which should be conducted to carry out the VICP.

The ACCV consists of nine members appointed by the Secretary as follows: Three health professionals, of whom at least two are pediatricians, who are not employees of the United States, who have expertise in the health care of children, the epidemiology, etiology and prevention of childhood diseases, and the adverse reactions associated with vaccines; three members from the general public, of whom at least two are legal representatives of children who have suffered a vaccine-related injury or death; and three attorneys, of whom at least one shall be an attorney whose specialty includes representation of persons who have suffered a vaccine-related injury or death and one shall be an attorney whose specialty includes representation of vaccine manufacturers. In addition, the Director of the National Institutes of Health, the Assistant Secretary for Health, the Director of the Centers for Disease Control and Prevention, and the Commissioner of the Food and Drug Administration (or the designees of such officials) serve as nonvoting ex officio members.

Specifically, HRSA is requesting nominations for three voting members of the ACCV representing: (1) A health professional with special experience in childhood diseases; (2) a member from the general public who is a legal representative of a child who has suffered a vaccine-related injury or death; and (3) an attorney whose specialty includes representation of persons who have suffered a vaccine-related injury or death. Nominees will be invited to serve 3-year terms beginning January 1, 1996, and ending December 31, 1998.

Interested persons may nominate one or more qualified persons for

membership on the ACCV. Nominations shall state that the nominee is willing to serve as a member of the ACCV and appears to have no conflict of interest that would preclude the ACCV membership. Potential candidates will be asked to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts to permit evaluation of possible sources of conflicts of interest. A curriculum vitae should be submitted with the nomination.

The Department of Health and Human Services has special interest in assuring that women, minority groups, and the physically handicapped are adequately represented on advisory committees and therefore extends particular encouragement to nominations for appropriately qualified female, minority, or physically handicapped candidates.

Dated: April 19, 1995.

Ciro V. Sumaya,
Administrator.

[FR Doc. 95-10175 Filed 4-25-95; 8:45 am]
BILLING CODE 4160-15-P

Substance Abuse and Mental Health Services Administration

Office for Women's Services; Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of a teleconference meeting of the Advisory Committee for Women's Services in May 1995.

The meeting will be held by telephone conference call. The meeting agenda of the Advisory Committee for Women's Services will include a discussion of women's substance abuse and mental health service needs within the context of the SAMHSA Strategic Plan, the proposed SAMHSA Performance Partnership grants, and proposed Policy Demonstration grants.

A summary of this meeting and/or a roster of committee members may be obtained from: Jennifer B. Fiedelholz, Executive Secretary, Advisory Committee for Women's Services, Office for Women's Services, Substance Abuse and Mental Health Services Administration, Parklawn Building, Room 13-99, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 443-5184.

Substantive information may be obtained from the contact whose name and telephone number is listed below.

Committee Name: Advisory Committee for Women's Services.

Meeting Date: May 22, 1995.

Place: Room 12-94, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857.

Open: 2:00 p.m. to adjournment.
Contact: Jennifer B. Fiedelholz, Room 13-99, Parklawn Building, Telephone (301) 443-5184.

Dated: April 20, 1995.

Jeri Lipov,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 95-10204 Filed 4-25-95; 8:45 am]
BILLING CODE 4162-20-P

DEPARTMENT OF THE INTERIOR

Bureau of Indian Affairs

Draft Environmental Impact Statement (DEIS) for the Yellowstone Pipeline Rights-of-Way Renewal Across Trust and Allotted Lands of the Flathead Indian Reservation, Montana

AGENCY: Bureau of Indian Affairs, Interior.

ACTION: Notice of availability of DEIS and public hearing dates.

SUMMARY: The Draft Environmental Impact Statement (DEIS) is for the proposed renewal of rights-of-way for an existing petroleum products pipeline. Constructed in 1954, this pipeline transports gasoline, diesel fuel, and jet fuel from refineries in Billings, Montana, 588 miles west to Spokane and Moses Lake, Washington. A portion of the pipeline crosses both tribal and allotted trust lands on the Flathead Indian Reservation in northwestern Montana.

The Yellowstone Pipe Line Company (YPL) and the Confederated Salish and Kootenai Tribes of the Flathead Nation (CSKT) executed a lease agreement for these trust lands for the period April 21, 1975, through April 21, 1995. It was approved by the Bureau of Indian Affairs (BIA), which serves as the federal trustee for the lands. The YPL requested a renewal of its lease from the CSKT in order to continue operating the pipeline through the year 2016.

A third party consultant, L.W. Reed Consultants, Inc. of Fort Collins, Colorado, is preparing the EIS for the BIA. They signed vouchers saying that they have no interest in the final decision of the BIA and have no conflict of interests involving YPL. The BIA required that YPL fund the EIS.

This notice is published pursuant to Sec. 1503.1 of the Council on Environmental Quality Regulations (40 CFR, Parts 1500 through 1508) implementing the procedural requirements of the National Environmental Policy Act of 1969, as amended (42 U.S.C. 4321 et seq.),

Department of Interior Manual (516 DM 1-6) and is in the exercise of authority delegated to the Assistant Secretary—Indian Affairs by 209 DM 8.

DATES: Public hearings on the DEIS will be held on the following dates: Thursday, May 11; Monday, May 15; Tuesday, May 16; Wednesday, May 17; and Thursday, May 18. Written comments must arrive on or before June 26, 1995, at the address given below. We will consider all comments received during this period in preparing the Final EIS.

ADDRESSES: Written comments may be submitted at the public meetings, or sent to: Mr. Ernest Moran, Superintendent, Flathead Agency, Box A, Pablo, MT 59855.

Public hearings on the DEIS will be held at the following locations and times: Cavanaugh's River Inn, Spokane, WA, Thursday May 11, 7 p.m.; Ruby's Reserve Street Inn, Missoula, MT, Monday May 15, 7 p.m.; St. Ignatius Community Center, St. Ignatius, MT, Tuesday May 16, 4 p.m.; CSKT Tribal Complex, Pablo, MT, Wednesday May 17, 11 a.m.; Tribal Senior Citizens Center, Hot Springs, MT, Thursday May 18, 4 p.m.

If you would like a copy of this DEIS, please contact Mr. Lanny Reed, Lanny Reed Consultants Inc., 516 Spring Canyon Court, Fort Collins, Colorado 80525, or call toll-free at (800) 695-9305. We have sent copies of the DEIS to all agencies and individuals who previously requested them.

FOR FURTHER INFORMATION CONTACT: Mr. Jim Beyer, Flathead Agency Box A, Pablo, Montana 59855, telephone (406) 675-7200 ext. 260, or you may call toll-free at (800) 695-9305.

SUPPLEMENTARY INFORMATION: The Department of the Interior classifies the renewal of an existing right-of-way "where there would be essentially no change in use and continuation would not lead to environmental degradation" as a Categorical Exclusion under NEPA. In this case, two large spills and five smaller ones on the Reservation during the life of the pipeline indicated that continuation might lead to significant environmental degradation. Therefore, the Superintendent of the Flathead Agency, BIA, in consultation with the CSKT, decided that an EIS would be required prior to any federal decision concerning lease renewal.

The Proposed Action consists of the YPL's request to renew existing rights-of-way across trust lands, with added pipeline safety improvements. The action is needed in order to continue: (1) Operation of the pipeline to serve the needs of the public; (2) transportation of